Santa Cruz Biotechnology

LEKTI (6A108) | Santa Cruz Biotechnology

mouse monoclonal IgG1; Lympho-epithelial Kazal-type inhibitor (LEKTI) is a serine protease inhibitor which protects mucous epithelia against microbial attack and inflammation. LEKTI is a marker of epithelial differentiation and expresses strongly in the granular and uppermost spinous layers of the epidermis and differentiated layers of stratified epithelia. Defects in SPINK5, the gene encoding LEKTI are the cause of Netherton syndrome, a severe autosomal recessive disorder characterized by atopic dermatitis, hayfever and other conditions.

Reviews


No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.